Emn Trial Office S.r.l. Impresa Sociale — Sponsor Intelligence | 14 EU Trials

Filter these 14 trials by condition, phase, country and more.

Open in Search →

14 Registered trials

6 Recruiting

8 Completed trials

18 Countries active

24 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 5 Phase II: 9

Oversight events:

3 temporary halts 1 unexpected event across 2 trials

View oversight register →

100%

8 of 8 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Amyloidosis 1

Top IMPs

DARATUMUMAB 7 LENALIDOMIDE 6 BORTEZOMIB 5 DEXAMETHASONE 4 TECLISTAMAB 4 DEXAMETHASONE SODIUM PHOSPHATE 3 TALQUETAMAB 2 BELANTAMAB MAFODOTIN 1 CARFILZOMIB 1 CILTACABTAGENE AUTOLEUCEL 1 CYCLOPHOSPHAMIDE 1 CYCLOPHOSPHAMIDE MONOHYDRATE 1

All trials

14 total

Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting

2024-520433-76-00 Phase II 4 countries DARATUMUMAB; TALQUETAMAB; TECLISTAMAB
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma Recruiting

2023-505775-70-00 Phase II 6 countries ELRANATAMAB; TOCILIZUMAB
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab… Recruiting

2024-519827-16-00 Phase III 16 countries DARATUMUMAB; DEXAMETHASONE; LENALIDOMIDE; LINVOSELTAMAB
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom… Recruiting

2023-507632-20-00 Phase III 9 countries BORTEZOMIB; CILTACABTAGENE AUTOLEUCEL; DARATUMUMAB; DEXAMETHASONE; LENALIDOMIDE
A study with new methods to monitor newly diagnosed multiple myeloma in participants being treated with a new treatment combination - TAURUS Recruiting

2023-505221-14-00 Phase II 5 countries BORTEZOMIB; DARATUMUMAB; IGG1 TRISPECIFIC MONOCLONAL ANTIBODY AGAINST T-CELL REC…
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia… Recruiting

2023-510384-36-00 Phase III 13 countries LENALIDOMIDE; TECLISTAMAB
A Trial of a novel agent in participants with previously treated Immunoglobulin Light-Chain (AL) Amyloidosis Ended

2024-519191-90-00 Phase II 5 countries TECLISTAMAB
A trial for relapsed Multiple Myeloma patients (Isatuximab-dexamethasone) Ended

2024-513397-21-00 Phase II 1 country DEXAMETHASONE SODIUM PHOSPHATE; ISATUXIMAB
Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended

2024-512354-21-00 Phase II 4 countries IBERDOMIDE
A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal… Ended

2024-513422-38-00 Phase III 8 countries CARFILZOMIB; DEXAMETHASONE; DEXAMETHASONE SODIUM PHOSPHATE; LENALIDOMIDE
Daratumumab combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extr… Ended

2024-514963-24-00 Phase II 2 countries BORTEZOMIB; DARATUMUMAB
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd… Ended

2024-511781-37-00 Phase II 3 countries BORTEZOMIB; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE MONOHYDRATE; DARATUMUMAB; DEXAMET…
A Study of combination of Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) compared to VELCADE, Lenalidomide, and … Ended

2023-506125-10-00 Phase III 11 countries BORTEZOMIB; DARATUMUMAB; LENALIDOMIDE
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis Ended

2024-513075-40-00 Phase II 5 countries BELANTAMAB MAFODOTIN

Showing 1–14 of 14 trials

← All sponsors A–Z